HPA Porton Down is a member of the UK Vaccine Evaluation Consortium, and assists the DH in the evaluation of new vaccines in clinical trials.
The Centre's GLP laboratories can also undertake contract testing for industry relating to vaccine assessment and batch testing of manufactured product prior to release.
For specific information please contact the centre directly.
Contact:
| Philip Luton | Business Development Officer, Commercial |
HPA Porton Down can assist young biotech companies wishing to develop their products from the laboratory to manufacture for clinical trials.
Our range of services include: cell banking, media development and yield optimisation, technology transfer, fermentation scale-up, purification development and production of non-GMP material prior to transfer to our licensed GMP facilities for both natural and recombinant products.
Contact:
| Philip Luton | Business Development Officer, Commercial |
HPA Porton Down has a number of licensed facilities for the manufacture of its own products. Spare capacity in these facilites is available for the GMP manufacture of biologicals.
Bacterial fermentations of up to 750 litres can be undertaken in our fermentation process plant. Other facilities include ones which can be utilised to manufacture products from organisms that require biological containment, for example Biodefence vaccines.
Contact:
| Philip Luton | Business Development Officer, Commercial |
| Philip Luton | Business Development Officer, Commercial |
Funding for Design of New State of the Art Facilities at Health Protection Agency’s Porton Down Site Announced (15 Sep 2008)
Funding to enable the design phase phase has been approved and made available by the UK government
Health Protection Agency to Design Laboratories for Samples from Mars (17 Jul 2008)
Facility to safely handle and protect samples
HPA receives Capacity Building Award (17 Jul 2008)
Public Sector Research Exploitation Fund: 4th Round.
Development of a Pan Meningococcal Vaccine for the World (22 Jan 2007)
The Health Protection Agency (UK) and the Serum Institute of India Ltd have announced that they have signed a royalty-bearing licence to develop a pentavalent vaccine for India and developing countries to combat all the principal forms of meningitis
Health Protection Agency and OPi Pharmaceuticals launch drug to help children fight leukaemia (22 Nov 2005)
A life-saving drug which offers potential benefit to children with leukaemia who have become allergic to front line therapies is to be produced by the Health Protection Agency in partnership with OPi Pharmaceuticals.
The Health Protection Agency (HPA) was formed on April 1st 2003 by bringing together various sections of the public health system. The Agency was set up to provide an integrated approach to protecting public health and reducing the effects of infections, poisons, chemical and radiation hazards.
Although a public sector body the Agency derrives a significant proportion of its annual turnover from commercial and contract work with UK and foreign governments, industry and academia.
The Agency conducts research into specific hazards to meet current and incipient health problems and to react to national emergencies, and has three national centres as well as a network of laboratories across the country.
The Agency's Centre at Porton Down has licensed GMP manufacturing facilities available for contract manufacture of biologics including recombinant proteins, enzymes and vaccines.
Specialist facilities for the handling of microbial pathogens exist to enable the development of diagnostic,prophylactic and therapeutic products from live agents, with particular reference to the biodefence sector.
Other capabilities include vaccine evaluation services from the development of assays to support for clinical trials, the supply of cell cultures and a wide range of diagnostic services.
© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd 
All rights reserved. Terms and Conditions | Contact us
